Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1035 studies found for:    DUAL-2
Show Display Options
Rank Status Study
1 Terminated
Has Results
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Conditions: Systemic Sclerosis;   Ulcers
Interventions: Drug: macitentan 3mg;   Drug: macitentan 10mg;   Drug: placebo
2 Recruiting PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Drug: Endocrine Therapy;   Drug: Paclitaxel
3 Unknown  Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Conditions: Chronic Hepatitis B;   Chronic Hepatitis D
Intervention: Drug: pegylated IFN alfa-2b plus ribavirin
4 Completed
Has Results
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide, long acting release;   Drug: exenatide
5 Recruiting Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors
Condition: Coronary Artery Disease
Intervention: Other: quit smoking for a 2 weeks period
6 Completed
Has Results
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Rosiglitazone;   Drug: Metformin
7 Recruiting Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES
Condition: Coronary Artery Disease
Interventions: Drug: P2Y12 antagonist monotherapy;   Drug: aspirin plus P2Y12 antagonist
8 Completed Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment (HM2)
Condition: Cognitive Impairment
Interventions: Behavioral: Exercise Intervention;   Behavioral: Exercise Control
9 Unknown  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Conditions: Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention: Drug: Peginterferon Alfa-2a plus Ribavirin
10 Completed Trial for People With Established Type 2 Diabetes During Ramadan
Condition: Type 2 Diabetes
Interventions: Drug: Liraglutide;   Drug: Sulfonylurea or Pioglitazone;   Drug: Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide
11 Completed The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: liraglutide;   Drug: exenatide
12 Completed Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: insulin degludec;   Drug: liraglutide
13 Active, not recruiting A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: insulin aspart
14 Completed A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
Condition: HIV Infections
Interventions: Drug: maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor);   Drug: maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor);   Drug: efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
15 Completed Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV);   Drug: Daclatasvir (DCV);   Drug: Pegylated-interferon alfa 2a (PegIFN);   Drug: Ribavirin (RBV)
16 Terminated
Has Results
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-195,543;   Drug: celecoxib;   Drug: Methotrexate
17 Terminated Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
Condition: Healthy Volunteers
Interventions: Drug: CG100649 (2 mg);   Drug: Celecoxib;   Drug: Placebo capsules;   Drug: Naproxen;   Drug: Acetazolamide;   Drug: CG100649 (8 mg)
18 Active, not recruiting Anticoagulation in Stent Intervention
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: Acetylsalicylic Acid + clopidogrel + acenocoumarol;   Drug: Acetylsalicylic Acid  + clopidogrel
19 Completed Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Gliclazide;   Drug: Metformin;   Drug: Placebo to Gliclazide;   Drug: Placebo to Vildagliptin
20 Completed A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide;   Drug: insulin glargine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years